Table 1.
Composition of prepared in situ gel formulations.
Table 2.
Composition of experimental design batches.
Table 3.
Physicochemical characteristics of preliminary in situ gel formulations.
Fig 1.
Rheology of in situ gels (M1–M8).
(A) Rheological behavior and (B) viscosity with and without simulated tear fluid (STF).
Fig 2.
Response surface graphs representing (A) gel strength (B) adhesive force (C) viscosity and (D) release of drug in 10 h.
Table 4.
Designed batches coded, uncoded values and evaluation of experimental design batches.
Fig 3.
Comparison of percentage moxifloxacin release from in situ gels (M1–M8), check point batches (MH8 and MH9) and drug solution (control).
The data represents average ± SD of six trials.
Fig 4.
Comparison of moxifloxacin ex vivo permeation across the isolated goat cornea membrane from optimized in situ gel (MH7) and control (commercial eye drops).
The data represents average ± SD of six trials.
Fig 5.
Comparison of mean moxifloxacin concentration in the aqueous humor following topical installation of optimized in situ gel (MH7) and control (commercial eye drops) in rabbits.
The data represents average ± SD of six trials.